Renal Fibrosis Model

NHP models of renal fibrosis, induced by unilateral ureteral obstruction (UUO) in the left kidney, show key changes including tubular dilation and increased collagen accumulation. These models are currently being explored to evaluate the potential of cell-based therapies to regenerate damaged kidney tissue and reduce fibrosis.

Send Inquiry

Product Introduction

Renal fibrosis, particularly tubulointerstitial fibrosis, is the final common pathway to end-stagerenal disease in almost all progressive chronic kidney diseases (CKD). It is characterized by excessive accumulation of extracellular matrix (ECM) proteins, primarily collagen, within the kidney interstitium, to loss of kidney function.

Many types of cells and cytokines contribute to the fibrotic process, predominantly macrophages, fibroblasts, and transforming growth factor-beta (TGF-β). These cells and mediators interact in a complex network to promote inflammation, fibroblast activation, and excessive ECM deposition.

The Unilateral Ureteral Obstruction (UUO) model is a well-established and frequently used experimental model of renal fibrosis. It resembles human obstructive nephropathy and allows researchers to study the mechanisms involved in the development and progression of renal fibrosis.

Understanding the Mechanisms of Renal Fibrosis

Renal fibrosis is a complex process with multiple contributing factors, and its exact cause often depends on the underlying kidney disease. However, several common pathways and mechanisms are involved in the development of renal fibrosis, regardless of the initial insult.
These include:

Chronic inflammation: Persistent inflammation within the kidney, often triggered by injury or disease, plays a central role in driving fibrosis. Inflammatory cells release cytokines and growth factors that promote fibroblast activation and ECM production.
TGF-β signaling: Transforming growth factor-beta (TGF-β) is a key mediator of fibrosis. It stimulates fibroblast proliferation, differentiation into myofibroblasts, and excessive ECM production.
Oxidative stress: An imbalance between reactive oxygen species (ROS) production and antioxidant defenses contributes to kidney damage and fibrosis. ROS can activate profibrotic signaling pathways and directly damage kidney cells.
Metabolic disturbances: Metabolic disorders, such as diabetes and obesity, can contribute to renal fibrosis through various mechanisms, including inflammation, oxidative stress, and advanced glycation end product (AGE) formation.
Genetic predisposition: Genetic factors may influence an individual's susceptibility to developing renal fibrosis in response to injury or disease.

Understanding the Diagnosis of Renal Fibrosis

The diagnosis of renal fibrosis often involves a

combination of clinical evaluation, laboratory tests, and

imaging studies.

Clinical evaluation: Assessing the patient's medical history, symptoms, and physical examination findings can provide clues about the underlying kidney disease and the presence of fibrosis.

Laboratory tests: Blood and urine tests can assess kidney function, identify markers of inflammation and kidney damage, and help diagnose the underlying kidney disease.

Imaging studies: Ultrasound, CT scans, and MRI can help visualize the kidneys and assess the extent of fibrosis and structural damage.

Kidney biopsy: In some cases, a kidney biopsy may be necessary to confirm the diagnosis and determine the underlying cause of renal fibrosis. This involves obtaining a small tissue sample from the kidney for microscopic examination.

It is important to identify and address the underlying

cause of renal fibrosis whenever possible, as this can

help slow the progression of the disease and preserve

kidney function.

Due to the high degree of similarity between the kidneys and immune systems of human and non-human primate (NHP) species, NHP models of renal fibrosis are invaluable for evaluating the efficacy and safety of novel therapeutic interventions.

The NHP models of renal fibrosis, particularly those utilizing techniques like unilateral ureteral obstruction (UUO) or specific nephrotoxic agents, closely mimic the key features of human chronic kidney disease (CKD) and its progression to fibrosis. These models exhibit:

Progressive renal fibrosis: NHP models demonstrate a gradual development of interstitial fibrosis, characterized by excessive deposition of extracellular matrix (ECM) proteins like collagen, mirroring the fibrotic process in human CKD.
Comparable histopathological features: NHP models exhibit histopathological features that closely resemble those observed in human renal fibrosis, including tubular atrophy, interstitial inflammation, and glomerulosclerosis.
Larger kidney size: The larger size of NHP kidneys allows for more detailed imaging and analysis of renal structure and function, facilitating a more comprehensive understanding of the disease process.
More similar drug metabolism: NHPs exhibit drug metabolism pathways that are more similar to humans compared to rodents, to more reliable predictions of drug efficacy and safety in clinical trials.

NHP models of renal fibrosis have been successfully utilized in pre-clinical evaluations of novel therapeutic agents for CKD, including:

Anti-fibrotic drugs: NHP models have been used to assess the efficacy of drugs targeting specific pathways involved in fibrosis, such as TGF-β signaling or inflammatory mediators.
Renoprotective therapies: NHP models have been employed to evaluate therapies aimed at protecting the kidney from further injury and slowing the progression of fibrosis.
Cell-based therapies: NHP models are being explored for the evaluation of cell-based therapies aimed at regenerating damaged kidney tissue and reducing fibrosis.

Therefore, NHP models of renal fibrosis provide a crucial platform for understanding the complex pathogenesis of CKD and for developing and testing new therapeutic strategies to combat this prevalent and debilitating condition. Their closer resemblance to human disease and their ability to provide more accurate predictions of drug efficacy and safety make them an invaluable tool in the fight against renal fibrosis.